Consistently, a bioinformatics analysis of pancreatic cancer-specific datasets from TCGA and the Cancer Therapeutics Response Portal (CTRP) identified CEACAM5 as a candidate stemness-related inhibitory ICP in pancreatic cancer. The gene discussed is CEACAM5; the disease is pancreatic neoplasm.